In this episode we will be talking to Dr. Graham Kelly, Chairman and CEO of Novogen Group (http://novogen.com).
Novogen is a publicly traded, Australian-US drug-development company whose shares trade on both the Australian Securities Exchange under ticker NRT and on the NASDAQ under NVGN. The Novogen group includes US-based, CanTx, Inc, a joint venture company with Yale University.
Novogen has two drug technology platforms yielding drug candidates that are first-in-class with potential application across a broad range of degenerative diseases. In the oncology field, the ultimate objective is to see both drug technologies used in combination as first-line therapy across most forms of cancer, with the objective of preventing tumor recurrence.
This objective is based on a strategy of achieving comprehensive destruction of the full hierarchy of cells within a tumor with the super-benzopyran technology platform killing the tumor-initiating cells and the anti-tropomyosin technology, combined with vinca alkaloids, to deliver a potent chemical debunking effect on their daughter cells.
For more information, please visit http://www.novogen.com.
Disclosure: Neither CEOLIVE.TV or any of its principals currently owns or plan to own within 72 hours of publication any shares of the stocks mentioned in this video. For a full disclaimer please visit, ceolive.tv/disclaimer.